AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11940751 — intervention group
Group type: COMPARATOR
Intervention: Forceps-dilational technique
Number of subjects: 100
Study 10652638 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 56
Study 10652638 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected relaxing music
Number of subjects: 56
Study 10652638 — intervention group
Group type: EXPERIMENTAL
Intervention: No music
Number of subjects: 56
Study 10652638 — intervention group
Group type: COMPARATOR
Intervention: Hard rock music
Number of subjects: 56
Study 10652638 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 56
Study 7829787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg)
Number of subjects: 52
Study 7829787 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 52
Study 7829787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg) during patch-off period
Number of subjects: 52
Study 7829787 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches during patch-off period
Number of subjects: 52
Study 7829787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg) during patch-on period
Number of subjects: 52
Study 7829787 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches during patch-on period
Number of subjects: 52
Study 2234817 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon panretinal photocoagulation
Number of subjects: 64
Study 2234817 — intervention group
Group type: COMPARATOR
Intervention: Krypton panretinal photocoagulation
Number of subjects: 64
Study 338397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotussin
Number of subjects: 50
Study 338397 — intervention group
Group type: COMPARATOR
Intervention: Linctus diphenhydramine
Number of subjects: 50
Study 30958829 — intervention group
Group type: EXPERIMENTAL
Intervention: STRETCH (task shifting intervention)
Number of subjects: 0
Study 30958829 — intervention group
Group type: COMPARATOR
Intervention: Control (ART)
Number of subjects: 0
Study 27053062 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 100
Study 27053062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 100
Study 27053062 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study 24934926 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW group (2 sets of 20 repetition maximum)
Number of subjects: 58
Study 24934926 — intervention group
Group type: COMPARATOR
Intervention: HIGH group (20 sets of 2 repetition maximum)
Number of subjects: 58
Study 24934926 — intervention group
Group type: COMPARATOR
Intervention: STAND group (standardised rehabilitation protocol)
Number of subjects: 58
Study 23295451 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy (VATS)
Number of subjects: 66
Study 23295451 — intervention group
Group type: COMPARATOR
Intervention: Open thoracotomy
Number of subjects: 66
Study 21689025 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of salmon (two meals per week)
Number of subjects: 0
Study 21689025 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet low in oily fish)
Number of subjects: 0
Study 18234905 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course antibiotic treatment (<= 5 days)
Number of subjects: 10698
Study 18234905 — intervention group
Group type: COMPARATOR
Intervention: Conventional longer antibiotic treatment (> 5 days)
Number of subjects: 10698
Study 16545881 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 21
Study 16545881 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 21
Study 14669316 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 200 mg orally three times daily (600 mg/day)
Number of subjects: 41
Study 14669316 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 41
Study 11027739 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041
Study 8996853 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained-release theophylline formulation (T1)
Number of subjects: 0
Study 8996853 — intervention group
Group type: EXPERIMENTAL
Intervention: New sustained-release theophylline formulation (T2)
Number of subjects: 0
Study 8996853 — intervention group
Group type: COMPARATOR
Intervention: Pellet formulation (R)
Number of subjects: 0
Study 1613812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine, 2 mg/h iv for 2 days
Number of subjects: 351
Study 1613812 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 351
Study 6238545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (active drug)
Number of subjects: 13
Study 6238545 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study 31257979 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Awareness Rating Scale - Movement Quality and Experience
Number of subjects: 35
Study 30846347 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training on a triangulation simulation model (30 minutes of training for 4 consecutive days)
Number of subjects: 36
Study 30846347 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 36
Study 29627227 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 69
Study 26903147 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly intensive aerobic exercise for 12 weeks (60 minutes per session, intensity up to exertion level 14 or 15 on the Borg scale)
Number of subjects: 56
Study 26903147 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly intensive aerobic exercise for 12 weeks
Number of subjects: 56
Study 24564888 — intervention group
Group type: EXPERIMENTAL
Intervention: shRNA knockdown of WNT5B (shWNT5B)
Number of subjects: 0
Study 24564888 — intervention group
Group type: COMPARATOR
Intervention: WNT5B overexpression
Number of subjects: 0
Study 23067272 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet based smoking cessation intervention
Number of subjects: 0
Study 19761492 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride, a selective 5-HT(4) agonist given orally once daily for 12 weeks
Number of subjects: 0
Study 19761492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18562740 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of bisacodyl
Number of subjects: 40
Study 18562740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of bisacodyl
Number of subjects: 40
Study 18562740 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of bisacodyl and 8.2 g of magnesium citrate
Number of subjects: 40
Study 18562740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of bisacodyl and 16.4 g of magnesium citrate
Number of subjects: 40
Study 18562740 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (30 mg of bisacodyl)
Number of subjects: 40
Study 16447661 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-resuscitation acupuncture method
Number of subjects: 90
Study 16447661 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (oral medication)
Number of subjects: 90
Study 11810086 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent oxytocin with sustained-release dinoprostone insert (immediate group)
Number of subjects: 71
Study 11810086 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin after removal of the dinoprostone insert (delayed group)
Number of subjects: 71
Study 10522600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 7
Study 10522600 — intervention group
Group type: COMPARATOR
Intervention: Trioleate
Number of subjects: 7
Study 7582225 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual placental removal with exteriorized uterine repair (group 4)
Number of subjects: 284
Study 7582225 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous placental removal and in situ uterine repair (group 1)
Number of subjects: 284
Study 7582225 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous placental removal and exteriorized uterine repair (group 2)
Number of subjects: 284
Study 7582225 — intervention group
Group type: COMPARATOR
Intervention: Manual placental removal and in situ uterine repair (group 3)
Number of subjects: 284
Study 1791685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) 160 mg/day
Number of subjects: 24
Study 1791685 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract (EGb 761) 80 mg/day
Number of subjects: 24
Study 1791685 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment by doctors and patients
Number of subjects: 24
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 34
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 34
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 34
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release Propranolol
Number of subjects: 34
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Slow-release Propranolol
Number of subjects: 34
Study 6814568 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Pindolol
Number of subjects: 34
Study 30837427 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR gene variation (677T and 1298A)
Number of subjects: 466
Study 30837427 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 466
Study 30837427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (male vs female)
Number of subjects: 466
Study 29295825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg plus standard of care (SoC) every 4 weeks until Week 48
Number of subjects: 677
Study 29295825 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (SoC) every 4 weeks until Week 48
Number of subjects: 677
Study 27460635 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia at 9.8% FIO2
Number of subjects: 10
Study 25409961 — intervention group
Group type: COMPARATOR
Intervention: Gcontrol: conventional respiratory physiotherapy
Number of subjects: 40
Study 25409961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gintra: PEEP at 10 cmH2O during surgery
Number of subjects: 40
Study 25409961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gpre: BiPAP before surgery for one hour
Number of subjects: 40
Study 25409961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gpos: BiPAP after surgery for one hour
Number of subjects: 40
Study 25409961 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Gpre, Gintra, Gpos)
Number of subjects: 40
Study 22385023 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA) weekly sessions for 5 weeks
Number of subjects: 18
Study 22385023 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention only weekly sessions for 5 weeks
Number of subjects: 18
Study 22385023 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 18
Study 20082362 — intervention group
Group type: COMPARATOR
Intervention: Minimum effective dose estimation
Number of subjects: 0
Study 20082362 — intervention group
Group type: COMPARATOR
Intervention: Nonlinear mixed effects models
Number of subjects: 0
Study 20082362 — intervention group
Group type: COMPARATOR
Intervention: Model selection step
Number of subjects: 0
Study 17646754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 0
Study 17646754 — intervention group
Group type: EXPERIMENTAL
Intervention: mitomycin C (MMC)
Number of subjects: 0
Study 17646754 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic agents (general)
Number of subjects: 0
Study 16134316 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique with X-ray tube voltage lowered to 53 kV
Number of subjects: 44
Study 16134316 — intervention group
Group type: COMPARATOR
Intervention: Standard technique with X-ray tube voltage at 69 kV
Number of subjects: 44
Study 12065553 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (MT) consisting of mercaptopurine and cytarabine for 18 months
Number of subjects: 268
Study 12065553 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (MT)
Number of subjects: 268
Study 9452837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent plantar compression
Number of subjects: 124
Study 9452837 — intervention group
Group type: COMPARATOR
Intervention: Sequential-gradient calf compression
Number of subjects: 124
Study 8542542 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for determining ejection fraction by Doppler echocardiography
Number of subjects: 114
Study 8542542 — intervention group
Group type: COMPARATOR
Intervention: Quinones method and single plane area length methods
Number of subjects: 114
Study 8542542 — intervention group
Group type: COMPARATOR
Intervention: Single plane multiple disc method
Number of subjects: 114
Study 8542542 — intervention group
Group type: COMPARATOR
Intervention: Quinones method
Number of subjects: 114
Study 8542542 — intervention group
Group type: COMPARATOR
Intervention: Single plane planimetry
Number of subjects: 114
Study 2090773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg orally prior to chemotherapy and repeated after 12 hours (Arm A)
Number of subjects: 53
Study 2090773 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Arm B)
Number of subjects: 53
Study 2090773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (Arm A)
Number of subjects: 53
Study 626712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 8‐methoxypsoralen followed by high‐intensity longwave ultraviolet treatment
Number of subjects: 15
Study 626712 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultraviolet light therapy
Number of subjects: 15
Study 626712 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 30793642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 100 mg IV
Number of subjects: 20
Study 30793642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg IV
Number of subjects: 20
Study 30793642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg IV
Number of subjects: 20
Study 30793642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 20
Study 31270429 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme on responsive feeding from birth to 24 months
Number of subjects: 468
Study 27611637 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane for 48 hours
Number of subjects: 50
Study 27611637 — intervention group
Group type: COMPARATOR
Intervention: Midazolam for 48 hours
Number of subjects: 50
Study 26293212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 59
Study 26293212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 59
Study 23578606 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac 37.5 mg
Number of subjects: 70
Study 23578606 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac 75 mg
Number of subjects: 70
Study 23578606 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (active control)
Number of subjects: 70
Study 23578606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 70
Study 20681817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (including oral hygiene instructions, scaling and root planing, and systemic antibiotic therapy)
Number of subjects: 30
Study 20681817 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 30
Study 19258557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K, 1.25 mg
Number of subjects: 724
Study 19258557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 17114017 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 183
Study 17114017 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) therapy
Number of subjects: 183
Study 15561384 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 15561384 — intervention group
Group type: COMPARATOR
Intervention: Skin non-penetrating placebo-acupuncture (Control)
Number of subjects: 0
Study 11281051 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose thiopentone (4 mg.kg‐1) administered just before laryngoscopy and intubation
Number of subjects: 76
Study 11281051 — intervention group
Group type: COMPARATOR
Intervention: Control group (thiopentone 4 mg.kg‐1 for induction, suxamethonium 1.5 mg.kg‐1 for muscle relaxation)
Number of subjects: 76
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity register inclusion
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant surgery contact since diagnosis
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant repeat prescription since diagnosis
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of myocardial infarction
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularisation procedure
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate assessment (smoking status, blood pressure, cholesterol)
Number of subjects: 1979
Study 11050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with aspirin or a lipid-lowering agent
Number of subjects: 1979
Study 8790170 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic CVC with silver sulfadiazine and chlorhexidine gluconate
Number of subjects: 72
Study 8790170 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC without antiseptics
Number of subjects: 72
Study 1536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with VAD regimen (vincristine, doxorubicin, dexamethasone) or VMCP regimen (vincristine, melphalan, cyclophosphamide, prednisone)
Number of subjects: 35
Study 1536941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan with total body irradiation supported by unpurged autologous bone marrow transplantation (ABMT)
Number of subjects: 35
Study 1536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alpha maintenance treatment
Number of subjects: 35
Study 1536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ABMT probability of progression-free survival
Number of subjects: 35
Study 1536941 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-diagnosis probability of survival
Number of subjects: 35
Study 6655706 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for couples not divorced or given additional therapy
Number of subjects: 140
Study 6655706 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples who separated
Number of subjects: 140
Study 6655706 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples given additional therapy
Number of subjects: 140
Study 31006959 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-based algorithm using 18 speech features
Number of subjects: 129
Study 31006959 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-PTSD veterans)
Number of subjects: 129
Study 30053899 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa floss from Qichun County, Hubei Province, China
Number of subjects: 350
Study 30053899 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxa floss from Nanyang County, Henan Province
Number of subjects: 350
Study 30053899 — intervention group
Group type: COMPARATOR
Intervention: Non-moxa floss (sham moxibustion)
Number of subjects: 350
Study 25716957 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic shielding (verum)
Number of subjects: 20
Study 25716957 — intervention group
Group type: COMPARATOR
Intervention: Visually identical placebo liners (placebo)
Number of subjects: 20
Study 25229556 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric electrode with 4 Hz low frequency stimulation (LFS)
Number of subjects: 16
Study 25229556 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix electrode with 4 Hz low frequency stimulation (LFS)
Number of subjects: 16
Study 25229556 — intervention group
Group type: COMPARATOR
Intervention: Matrix electrode with 30 Hz (sham condition)
Number of subjects: 16
Study 23201764 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention instructions
Number of subjects: 171
Study 23201764 — intervention group
Group type: COMPARATOR
Intervention: No implementation intention instructions (Control)
Number of subjects: 171
Study 20082586 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (2 mg)
Number of subjects: 20
Study 20082586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 20
Study 20082586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20082586 — intervention group
Group type: COMPARATOR
Intervention: Control (no diabetes)
Number of subjects: 20
Study 17655982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified mother's milk (FMM) with individualized supplementation of minerals and protein
Number of subjects: 120
Study 17655982 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula milk (PF)
Number of subjects: 120
Study 17655982 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified mother's milk (FMM)
Number of subjects: 120
Study 15765257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (mixed D1/D2 agonist)
Number of subjects: 40
Study 15765257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (D2 selective agonist)
Number of subjects: 40
Study 15765257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12233877 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-α therapy
Number of subjects: 175
Study 12233877 — intervention group
Group type: COMPARATOR
Intervention: GG genotype prevalence
Number of subjects: 175
Study 9817404 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour methylprednisolone (24MP)
Number of subjects: 0
Study 9817404 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour methylprednisolone (48MP)
Number of subjects: 0